|
|
Article: CombinatoRx and Neuromed Announce Posting of Briefing Documents for FDA Advisory Committee.
- Article from:
- Business Wire
- Article date:
- September 22, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. and VANCOUVER, B.C. -- CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the September 23, 2009 joint meeting of its Anesthetics and Life Support Advisory Committee and its Drug Safety and Risk Management Advisory Committee. At the meeting, the committees will review and discuss Neuromed's New Drug Application (NDA) for Exalgo[TM] (hydromorphone HCI extended release) tablets seeking FDA approval for the management of moderate to severe pain in opioid tolerant patients ...